-
|
Benzinga –
4:44 AM ET 06/21/2022
|
-
|
GlobeNewswire –
4:05 PM ET 06/16/2022
Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET Vaxart, Inc. (VXRT) today announced that it will host a question-and-answer webcast with investors and analysts on Wednesday, June 22, 2022, at 1:00 p.m. Eastern Time. The Company will take written questions from investors and analysts.
|
-
|
Reuters –
9:12 AM ET 06/08/2022
Vaxart Inc (VXRT): * VAXART ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
9:05 AM ET 06/08/2022
Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart (VXRT) encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN FRANCISCO, Calif., June 08, 2022 -- Vaxart (VXRT), Inc. announced today that its 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022 at 9:30 a.m. Pacific Time with respect to a...
|
-
|
Reuters –
8:06 AM ET 06/03/2022
Vaxart Inc (VXRT): * NEW PRECLINICAL DATA DEMONSTRATE TWO OF VAXART'S COVID-19 VACCINE CANDIDATES PROTECT AGAINST OMICRON Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 06/03/2022
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates Vaxart, Inc. (VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant.
|
-
|
Reuters –
8:33 AM ET 06/02/2022
Vaxart Inc (VXRT): * VAXART REPORTS POSITIVE PRELIMINARY DATA FROM THE PHASE 1B TRIAL OF ITS ORAL NOROVIRUS VACCINE CANDIDATES IN ELDERLY ADULTS. * Vaxart Inc (VXRT) - RESULTS SUPPORT SAFETY AND IMMUNOGENICITY OF VACCINE CANDIDATE IN HIGHLY VULNERABLE ELDERLY POPULATION Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:30 AM ET 06/02/2022
Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to cost the United States $10.6 billion annually SOUTH SAN FRANCISCO, Calif., June 02, 2022 -- Vaxart (VXRT) today reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candid...
|
-
|
GlobeNewswire –
8:00 AM ET 06/02/2022
Vaxart, Inc. (VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 9, 2022 at 10:30 a.m. ET.
|
-
|
GlobeNewswire –
8:30 AM ET 05/19/2022
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2.
|
-
|
GlobeNewswire –
5:35 PM ET 05/13/2022
Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Vaxart, Inc. (VXRT) breached their fiduciary duties of loyalty, good faith and candor and whether the Company suffered substantial harm as a result.
|
-
|
Reuters –
5:42 PM ET 05/11/2022
Vaxart Inc (VXRT): * Vaxart Inc (VXRT)- ON MAY 10 CO RETAINED FUAD AHMAD AS CO'S INTERIM CFO WHILE VAXART CONDUCTS ITS ONGOING SEARCH FOR A CHIEF FINANCIAL OFFICER Source text for Eikon: [https://bit.ly/3Pccrqn] Further company coverage:
|
-
|
Benzinga –
12:28 PM ET 05/11/2022
On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
Benzinga –
8:22 AM ET 05/10/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Reuters –
5:47 PM ET 05/09/2022
Vaxart Inc (VXRT): * VAXART PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.20 Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
5:46 PM ET 05/09/2022
Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities Vaxart (VXRT), Inc. issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.
|
-
|
Benzinga –
3:31 PM ET 04/28/2022
During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
Benzinga –
2:41 PM ET 04/27/2022
Wednesday's session saw 784 companies set new 52-week lows. The following stocks set new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
Benzinga –
1:44 PM ET 04/26/2022
During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
Benzinga –
12:01 PM ET 04/25/2022
On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.
|
Page:
|
Today's and Upcoming Events
-
VXRT to announce Q2 earnings (Unconfirmed)
Past Events (last 90 days)
-
VXRT announced Q1 earnings.
Data provided by Thomson Reuters © 2022
|